Sense Biodetection Funding: $79M Raised, Series B (2021)
Sense Biodetection is based in Abingdon, United Kingdom. It has raised $79M in total funding. Latest round: Series B.
Sense Biodetection funding overview
Sense Biodetection is based in Abingdon, United Kingdom. Sense Biodetection has raised $79M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in January 2021. The round record for Sense Biodetection runs through 2021; nothing later has been disclosed. Investors on record include Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health, Mercia Asset Management, Gov.uk, Sherlock Biosciences. 6 distinct backers are named across the disclosed rounds.
Sense Biodetection has raised $79M in total disclosed funding across the rounds on record.
Who has invested in Sense Biodetection?
Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health, Mercia Asset Management, Gov.uk, Sherlock Biosciences are named among the investors backing Sense Biodetection.
What was the latest Sense Biodetection funding round?
The most recent disclosed round is a Series B, announced in January 2021.
Where is Sense Biodetection based?
Sense Biodetection is based in Abingdon, United Kingdom.
When did Sense Biodetection last raise?
The last disclosed Sense Biodetection round closed in January 2021 at Series B.
We update the Sense Biodetection record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Abingdon and their backers are listed below.
